AU2014349246C1 - Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases - Google Patents
Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases Download PDFInfo
- Publication number
- AU2014349246C1 AU2014349246C1 AU2014349246A AU2014349246A AU2014349246C1 AU 2014349246 C1 AU2014349246 C1 AU 2014349246C1 AU 2014349246 A AU2014349246 A AU 2014349246A AU 2014349246 A AU2014349246 A AU 2014349246A AU 2014349246 C1 AU2014349246 C1 AU 2014349246C1
- Authority
- AU
- Australia
- Prior art keywords
- eosinophilic
- diseases
- compound
- atopic dermatitis
- bronchial asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018264084A AU2018264084C1 (en) | 2013-11-14 | 2018-11-15 | Pharmaceutical composition comprising glutarimide derivatives, and application thereof for treating eosinophilic diseases |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013150861/15A RU2552929C1 (ru) | 2013-11-14 | 2013-11-14 | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| RU2013150861 | 2013-11-14 | ||
| PCT/RU2014/000855 WO2015072893A1 (ru) | 2013-11-14 | 2014-11-12 | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018264084A Division AU2018264084C1 (en) | 2013-11-14 | 2018-11-15 | Pharmaceutical composition comprising glutarimide derivatives, and application thereof for treating eosinophilic diseases |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| AU2014349246A1 AU2014349246A1 (en) | 2016-05-19 |
| AU2014349246A9 AU2014349246A9 (en) | 2018-09-20 |
| AU2014349246B2 AU2014349246B2 (en) | 2018-10-18 |
| AU2014349246C1 true AU2014349246C1 (en) | 2019-02-21 |
Family
ID=53057723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014349246A Ceased AU2014349246C1 (en) | 2013-11-14 | 2014-11-12 | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases |
| AU2018264084A Ceased AU2018264084C1 (en) | 2013-11-14 | 2018-11-15 | Pharmaceutical composition comprising glutarimide derivatives, and application thereof for treating eosinophilic diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018264084A Ceased AU2018264084C1 (en) | 2013-11-14 | 2018-11-15 | Pharmaceutical composition comprising glutarimide derivatives, and application thereof for treating eosinophilic diseases |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9949962B2 (OSRAM) |
| EP (2) | EP3069720B1 (OSRAM) |
| JP (4) | JP2016540749A (OSRAM) |
| KR (2) | KR102312013B1 (OSRAM) |
| CN (2) | CN105722511B (OSRAM) |
| AU (2) | AU2014349246C1 (OSRAM) |
| BR (1) | BR112016010515B1 (OSRAM) |
| CA (1) | CA2930231C (OSRAM) |
| CY (1) | CY1122500T1 (OSRAM) |
| DK (1) | DK3069720T3 (OSRAM) |
| EA (4) | EA030961B1 (OSRAM) |
| ES (2) | ES2836887T3 (OSRAM) |
| HU (1) | HUE046671T2 (OSRAM) |
| IL (2) | IL245429B (OSRAM) |
| LT (1) | LT3069720T (OSRAM) |
| MX (2) | MX386887B (OSRAM) |
| PL (2) | PL3069720T3 (OSRAM) |
| PT (1) | PT3069720T (OSRAM) |
| RU (1) | RU2552929C1 (OSRAM) |
| SG (1) | SG10201900504XA (OSRAM) |
| SI (1) | SI3069720T1 (OSRAM) |
| UA (1) | UA118687C2 (OSRAM) |
| WO (1) | WO2015072893A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| KR102576903B1 (ko) | 2012-09-07 | 2023-09-13 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법 |
| EP3725785B1 (en) * | 2013-04-12 | 2024-04-10 | Nebolsin, Vladimir | Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| KR102927870B1 (ko) | 2014-02-28 | 2026-02-19 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| US11771743B2 (en) | 2016-09-01 | 2023-10-03 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an IL-4R antagonist |
| CN106539792B (zh) * | 2016-11-07 | 2017-08-25 | 王晓旭 | 一种治疗高血脂症的药物 |
| GEP20227402B (en) * | 2017-09-07 | 2022-08-10 | Valenta Intellekt Ltd | Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines |
| RU2712281C1 (ru) * | 2018-11-23 | 2020-01-28 | Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма |
| SG11202109002XA (en) | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| AU2020325021B2 (en) | 2019-08-05 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
| EP4010373A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| EP4132571B1 (en) * | 2020-04-07 | 2025-10-29 | Hofseth Biocare ASA | Salmonid oil compositions for use in the treatment of eosinophilic related inflammatory and respiratory conditions |
| MA58653B1 (fr) * | 2020-06-26 | 2024-02-29 | Valenta Intellekt Ltd | Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 |
| WO2023113650A1 (ru) * | 2021-12-15 | 2023-06-22 | Владимир Евгеньевич НЕБОЛЬСИН | Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994024133A1 (en) * | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196767A (ja) * | 1988-10-11 | 1990-08-03 | Kyowa Hakko Kogyo Co Ltd | ヒドロキサム酸誘導体 |
| AU9134191A (en) * | 1990-12-24 | 1992-07-22 | Merrell Dow Pharmaceuticals Inc. | Use of certain glutarimide derivatives in the treatment of depression and mania |
| AUPO005496A0 (en) | 1996-05-24 | 1996-06-13 | Bresagen Limited | An interleukin-5 antagonist |
| RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| ES2320638T3 (es) | 2001-11-07 | 2009-05-27 | Cytos Biotechnology Ag | Disposicion ordenada de antigenos il-5, il-13 o eotasina, para el tratamiento de enfermedades alergicas con un componente eosinofilico. |
| EP1741709A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| WO2007007054A1 (en) | 2005-07-08 | 2007-01-18 | Cancer Research Technology Limited | Phthalamides, succinimides and related compounds and their use as pharmaceuticals |
| DK3072525T3 (en) | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
| RU2406727C2 (ru) * | 2008-02-13 | 2010-12-20 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств |
| RU2378284C2 (ru) * | 2008-02-13 | 2010-01-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способы получения n-ацильных производных аминокислот (варианты) |
| EP3725785B1 (en) | 2013-04-12 | 2024-04-10 | Nebolsin, Vladimir | Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative |
-
2013
- 2013-11-14 RU RU2013150861/15A patent/RU2552929C1/ru active
-
2014
- 2014-11-12 PL PL14861410T patent/PL3069720T3/pl unknown
- 2014-11-12 BR BR112016010515-0A patent/BR112016010515B1/pt not_active IP Right Cessation
- 2014-11-12 HU HUE14861410A patent/HUE046671T2/hu unknown
- 2014-11-12 WO PCT/RU2014/000855 patent/WO2015072893A1/ru not_active Ceased
- 2014-11-12 MX MX2019006881A patent/MX386887B/es unknown
- 2014-11-12 LT LTEP14861410.0T patent/LT3069720T/lt unknown
- 2014-11-12 EA EA201690798A patent/EA030961B1/ru not_active IP Right Cessation
- 2014-11-12 EP EP14861410.0A patent/EP3069720B1/en active Active
- 2014-11-12 PL PL18206980T patent/PL3466425T3/pl unknown
- 2014-11-12 EA EA201990529A patent/EA037447B1/ru unknown
- 2014-11-12 PT PT148614100T patent/PT3069720T/pt unknown
- 2014-11-12 CN CN201480062492.5A patent/CN105722511B/zh not_active Expired - Fee Related
- 2014-11-12 SI SI201431407T patent/SI3069720T1/sl unknown
- 2014-11-12 DK DK14861410T patent/DK3069720T3/da active
- 2014-11-12 US US15/036,603 patent/US9949962B2/en active Active
- 2014-11-12 EA EA201891261A patent/EA032940B1/ru not_active IP Right Cessation
- 2014-11-12 CA CA2930231A patent/CA2930231C/en active Active
- 2014-11-12 KR KR1020207013125A patent/KR102312013B1/ko not_active Expired - Fee Related
- 2014-11-12 JP JP2016530898A patent/JP2016540749A/ja not_active Ceased
- 2014-11-12 AU AU2014349246A patent/AU2014349246C1/en not_active Ceased
- 2014-11-12 ES ES18206980T patent/ES2836887T3/es active Active
- 2014-11-12 MX MX2016006330A patent/MX365781B/es active IP Right Grant
- 2014-11-12 EA EA201891262A patent/EA032955B3/ru not_active IP Right Cessation
- 2014-11-12 KR KR1020167013675A patent/KR102312294B1/ko not_active Expired - Fee Related
- 2014-11-12 EP EP18206980.7A patent/EP3466425B1/en active Active
- 2014-11-12 SG SG10201900504XA patent/SG10201900504XA/en unknown
- 2014-11-12 CN CN201910373584.XA patent/CN110200968A/zh active Pending
- 2014-11-12 ES ES14861410T patent/ES2759530T3/es active Active
- 2014-12-11 UA UAA201606370A patent/UA118687C2/uk unknown
-
2016
- 2016-05-01 IL IL245429A patent/IL245429B/en active IP Right Grant
-
2017
- 2017-12-18 US US15/844,703 patent/US10220029B2/en active Active
-
2018
- 2018-10-30 JP JP2018203599A patent/JP6589251B2/ja active Active
- 2018-11-15 AU AU2018264084A patent/AU2018264084C1/en not_active Ceased
-
2019
- 2019-08-21 JP JP2019151258A patent/JP2020002152A/ja not_active Ceased
- 2019-08-21 JP JP2019151253A patent/JP6758677B2/ja not_active Expired - Fee Related
- 2019-11-19 CY CY20191101215T patent/CY1122500T1/el unknown
- 2019-12-11 IL IL271352A patent/IL271352B/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994024133A1 (en) * | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014349246B2 (en) | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases | |
| WO2017167182A1 (zh) | 一种选择性的c-kit激酶抑制剂 | |
| KR102418211B1 (ko) | 일시적 수용체 전위 a1 이온 채널의 억제 | |
| JP2022521964A (ja) | 新型汎ｒａｆキナーゼ阻害剤及びその使用 | |
| HK40007097A (en) | Use of glutarimide derivatives in the treatment of eosinophilic diseases | |
| HK40007097B (en) | Use of glutarimide derivatives in the treatment of eosinophilic diseases | |
| CN111138426B (zh) | 吲唑类激酶抑制剂及其用途 | |
| HK1224930B (zh) | 包含戊二酰亚胺衍生物的药物组合物及其用於治疗嗜酸细胞性疾病的用途 | |
| HK1224930A1 (en) | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 NOV 2018 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 09 NOV 2018 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: CHEMIMMUNE THERAPEUTICS LIMITED LIABILITY COMPAN Free format text: FORMER OWNER(S): OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |